GlassScriptPhysician profile
Michelle A Costello
NPI 1528238524
$803.91
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.90 · 2022: $113 · 2023: $501 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $188.75 | 2023-2024 | Veozah, Myrbetriq |
| Organon LLC | $82.42 | 2021-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $76.35 | 2023 | |
| Sumitomo Pharma America, INC. | $72.61 | 2023-2024 | Myfembree, Gemtesa |
| Pfizer INC. | $53.33 | 2021-2024 | |
| Exeltis, USA INC. | $51.55 | 2021-2023 | Slynd |
| Agile Therapeutics, INC. | $43.42 | 2022-2023 | Twirla |
| Shield Therapeutics INC | $37.97 | 2023 | Accrufer |
| Mycovia Pharmaceuticals, INC. | $36.12 | 2023 | Vivjoa |
| Pacira Pharmaceuticals Incorporated | $31.06 | 2024 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $24.02 | 2021 | |
| Abbvie INC. | $21.88 | 2023 | |
| Millicent US INC | $19.93 | 2023 | Intrarosa |
| Merck Sharp & Dohme LLC | $19.59 | 2023 | Gardasil 9 |
| Coopersurgical, INC. | $17.25 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $14.96 | 2022 | |
| Therapeuticsmd, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Costello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.